Abstract
Low-density lipoprotein cholesterol (LDL-C) is a well-established major cardiovascular (CV) risk factor supported by clinical evidence showing decreased atherosclerotic disease events when LDL-C is therapeutically lowered. A reasonable approach is to tailor each patient’s LDL-C target level depending on the initial LDL-C level and the perceived risk. Multiple clinical entities such as the newborn, hypobetalipoproteinemia, proprotein convertase subtilisin/kexin type 9 (PCSK9) missense mutations, and an unexpected excess response to a statin or other medications, are associated with very low LDL-C levels in otherwise healthy individuals. Therefore, an issue of major interest to clinicians who buy into “lower is better” for LDL-C in the high-risk CV patient is how low can and should the LDL-C be taken? Available information is discussed and placed into context. A definite safe lowest LDL-C level cannot be specified but there appears to be support that a level as low as 20 mg/dL (0.52 mmol/l) can be justified in the highest CV risk patients with extensive atherosclerosis where plaque stabilization and regression are necessary.
Keywords: Coronary artery disease, low-density lipoprotein cholesterol, peripheral arterial disease, proprotein convertase subtilisin/ kexin type 9, statins.
Current Vascular Pharmacology
Title:Low-Density Lipoprotein Cholesterol (LDL-C): How Low?
Volume: 15 Issue: 4
Author(s): Thomas F. Whayne*
Affiliation:
- Wethington Building, 900 South Limestone Street, Lexington, KY 40536-0200,United States
Keywords: Coronary artery disease, low-density lipoprotein cholesterol, peripheral arterial disease, proprotein convertase subtilisin/ kexin type 9, statins.
Abstract: Low-density lipoprotein cholesterol (LDL-C) is a well-established major cardiovascular (CV) risk factor supported by clinical evidence showing decreased atherosclerotic disease events when LDL-C is therapeutically lowered. A reasonable approach is to tailor each patient’s LDL-C target level depending on the initial LDL-C level and the perceived risk. Multiple clinical entities such as the newborn, hypobetalipoproteinemia, proprotein convertase subtilisin/kexin type 9 (PCSK9) missense mutations, and an unexpected excess response to a statin or other medications, are associated with very low LDL-C levels in otherwise healthy individuals. Therefore, an issue of major interest to clinicians who buy into “lower is better” for LDL-C in the high-risk CV patient is how low can and should the LDL-C be taken? Available information is discussed and placed into context. A definite safe lowest LDL-C level cannot be specified but there appears to be support that a level as low as 20 mg/dL (0.52 mmol/l) can be justified in the highest CV risk patients with extensive atherosclerosis where plaque stabilization and regression are necessary.
Export Options
About this article
Cite this article as:
Whayne F. Thomas*, Low-Density Lipoprotein Cholesterol (LDL-C): How Low?, Current Vascular Pharmacology 2017; 15 (4) . https://dx.doi.org/10.2174/1570161115666170227102708
DOI https://dx.doi.org/10.2174/1570161115666170227102708 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review of Feature Extraction from ECG Signals and Classification/ Detection for Ventricular Arrhythmias
Recent Advances in Computer Science and Communications Pharmacogenetically Tailored Treatments for Heart Disease
Current Pharmaceutical Design Decrease in Secondary Neck Vessels in Multiple Sclerosis: A 5-year Longitudinal Magnetic Resonance Angiography Study
Current Neurovascular Research An Overview of the Modulatory Effects of Oleic Acid in Health and Disease
Mini-Reviews in Medicinal Chemistry Treatments for Hypertension in Type 2 Diabetes-Non-pharmacological and Pharmacological Measurements<sup>#</sup>
Current Hypertension Reviews Untargeted Metabolomics in the Discovery of Novel Biomarkers and Therapeutic Targets for Atherosclerotic Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Retrospective, Observation Study: Quantitative and Qualitative Effect of Ezetimibe and HMG-CoA Reductase Inhibitors on LDL-Cholesterol: Are There Disappearance Thresholds for Small, Dense LDL and IDL?
Recent Patents on Cardiovascular Drug Discovery Understanding the Concept of Chronotherapeutics in the Management of Diabetes Mellitus
Current Diabetes Reviews Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Xanthones from Mangosteen Extracts as Natural Chemopreventive Agents: Potential Anticancer Drugs
Current Molecular Medicine Overview of Therapeutic Potential of Rapamycin for Coronary Artery Diseases in the Era of the Drug-Eluting Stent
Vascular Disease Prevention (Discontinued) Nebulizer Therapy in Pulmonology: Review of the Literature
Current Respiratory Medicine Reviews Combination Therapy of Statins with Ezetimibe
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Polyphenols Effect on Circulating Lipids and Lipoproteins: From Biochemistry to Clinical Evidence
Current Pharmaceutical Design Chymase as an Important Target for Preventing Complications of Metabolic Syndrome
Current Medicinal Chemistry Potential of Selected Indian Herbs for COVID-19
Current Traditional Medicine Editorial (Thematic Issue: Biochemical Targets and Biomarkers for Central Nervous System Protection and Monitoring)
CNS & Neurological Disorders - Drug Targets Iron Involvement in Multiple Signaling Pathways of Atherosclerosis: A Revisited Hypothesis
Current Medicinal Chemistry Recent Advancement in the Treatment of Cardiovascular Diseases: Conventional Therapy to Nanotechnology
Current Pharmaceutical Design The Use of Ghrelin and Ghrelin Receptor Agonists as a Treatment for Animal Models of Disease: Efficacy and Mechanism
Current Pharmaceutical Design